Dosimetric analysis of the effects of the bladder volume on Organs at Risk (OARs) in high-dose-rate intracavitary brachytherapy in locally advanced carcinoma cervix (Stage IB3, IIA2, IIB–IVA)

Background: Cervical cancer remains a major cause of morbidity and mortality world-wide, particularly in low- and middle-income countries. Intracavitary brachytherapy is integral to definitive treatment but exposes adjacent organs at risk (OARs) to potentially harmful radiation doses. The influence of bladder volume on dosimetry remains controversial. Methods: This retrospective study included 90 patients with Federation of Gynecology and Obstetrics (FIGO) 2018 stage IB3–IVA cervical carcinoma, treated at Ahsania Mission Cancer and General Hospital, Dhaka (2019–2020). Patients were stratified into three groups based on bladder volume: Group A (0–40 cc), Group B (41–80 cc), and Group C (81–120 cc). All received standard chemoradiation followed by High-Dose-Rate (HDR) intracavitary brachytherapy. Dosimetric parameters (D2cc Equivalent Dose in 2 Gy fractions (EQD2) for bladder, rectum, and sigmoid) and High-Risk Clinical Target Volume (HR-CTV) D90 coverage were analyzed. Early response at 6–8 weeks was also assessed. Results: Mean bladder D2cc was 85.6 Gy (Group A), 73.2 Gy (Group B), and 78.9 Gy (Group C), with Group B significantly lower (p = 0.002). Rectal D2cc followed a similar trend (70.2 Gy, 64.5 Gy, and 72.4 Gy; p = 0.01). Sigmoid D2cc showed no significant variation (p = 0.41). HR-CTV D90 remained comparable across groups (82.8–84.2 Gy; p = 0.48). Complete response was achieved in 73.3% of patients, with no significant difference between groups (p = 0.57). Conclusions: A moderately filled bladder (∼60 cc) provides the most favorable dosimetric profile, significantly reducing bladder and rectal doses while maintaining adequate tumor coverage. Standardizing bladder filling protocols may enhance treatment safety and consistency in HDR brachytherapy for cervical cancer.

Bladder volume; HDR brachytherapy; Cervical cancer; Dosimetry; Organs at risk

[1] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians. 2024; 74: 12–49.

[2] Cibula D, Raspollini MR, Planchamp F, Centeno C, Chargari C, Felix A, et al. ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer—update 2023. International Journal of Gynecological Cancer. 2023; 33: 649–666.

[3] Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecological Cancer. 2019; 145: 129–135.

[4] NCCN. NCCN guidelines: cervical cancer. 2025. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1426 (Accessed: 28 October 2025).

[5] Chen FP, Cao XP. Image-guided adaptive brachytherapy for cancer of the cervix: current status and future directions. Holistic Integrative Oncology. 2025; 4: 44.

[6] Zhou K, Wang C, Zhao J, Chen J, An X, Yin Y, et al. Dosimetric effects of bladder volume changes in MR-guided radiotherapy for cervical cancer. BMC Cancer. 2025; 25: 324.

[7] Swamidas J, Mahantshetty U. ICRU report 89: prescribing, recording, and reporting brachytherapy for cancer of the cervix. Journal of Medical Physics. 2017; 42: 48.

[8] Ma J, Bai F. Effect of different bladder water injection volumes on target area dose and OAR in 129 cases of radical cervical cancer treated with intracavitary brachytherapy: a real-world study. International Journal of Radiation Oncology, Biology, Physics. 2024; 120: e163.

[9] Osaki N, Soyano T, Sutani S, Matsumoto H, Takeda A, Yorozu A. Comparison of rectal and bladder dose between retractor insertion and gauze packing in intracavitary brachytherapy for cervical cancer. Journal of Radiation Research. 2025; 66: 528–534.

[10] Ye BQ, Zhao CZ, Sun PF. Variations and effects of bladder and rectal volume following uniform preparation procedure in cervical cancer: five fractions of 6 Gy. Journal of Contemporary Brachytherapy. 2023; 15: 123–129.

[11] Harmon G, Chinsky B, Surucu M, Harkenrider M, Small W. Bladder distension improves the dosimetry of organs at risk during intracavitary cervical high-dose-rate brachytherapy. Brachytherapy. 2016; 15: 30–34.

[12] Sharma AD, Poddar J, Suryanarayan KU, Shah SP, Parikh A, Mehta V, et al. Dosimetric analysis of the effects of the bladder volume on organs at risk (OAR) in high-dose-rate intracavitary brachytherapy in carcinoma cervix—an institutional study. Journal of Contemporary Brachytherapy. 2018; 10: 26–31.

[13] De Sanctis V, Facondo G, Vullo G, Anzellini D, Sanguineti G, Nardangeli A, et al. Clinical outcomes and toxicity of CT-guided high dose-rate brachytherapy in women with locally-advanced cervical cancer. Cancer Diagnosis & Prognosis. 2023; 3: 194–200.

[14] Aghili M, Babaei M, Bayani R, Jaberi R, Amouzegar Hashemi F, Kalaghchi B, et al. Short course brachytherapy in locally advanced cervical cancer; safety and response rate. Asian Pacific Journal of Cancer Prevention. 2024; 25: 3119–3124.

[15] Major-Elechi BT, Sloan JA, Novotny PJ, Sargent DJ, Grothey A, Lafky JM, et al. The clinical significance of effect sizes for survival and tumor response endpoints using the empirical rule effect size. Journal of Biometrics & Biostatistics. 2019; 10: 1000433.